Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336772 | 0.95 | NPC1 (0.46) | NPC1RAB9AHPGDKCNK3KCNK9 | |
| SCHEMBL2038760 | 0.84 | ACHE (0.53) | HPGDERCC5FEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3461999 | 0.78 | NPC1 (0.44) | NPC1RAB9AHPGDKCNK3KCNK9 | |
| SCHEMBL4711341 | 0.76 | NPC1 (0.43) | NPC1RAB9AHPGDKCNK3KCNK9 | |
| SCHEMBL236 | 0.76 | AKR1C3 (0.61) | NPC1RAB9AHPGDKCNK3KCNK9 | |
| SCHEMBL6445437 | 0.76 | KMT2A (0.45) | NPC1RAB9AHPGDKCNK3KCNK9 | |
| SCHEMBL11757827 | 0.76 | ALDH1A1 (0.49) | NPC1RAB9AHPGDKCNK3KCNK9 | |
| SCHEMBL11108075 | 0.76 | CYP1A2 (0.49) | NPC1RAB9AHPGDKCNK3KCNK9 | |
| SCHEMBL9451511 | 0.76 | AKR1C3 (0.61) | NPC1RAB9AHPGDKCNK3KCNK9 | |
| SCHEMBL29883083 | 0.76 | KMT2A (0.45) | NPC1RAB9AHPGDKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110291099-B | Synthesis of Liraglutide | 拜康有限公司 | 2024-06-21 | — | — | CN | claimed |
| EP-4380962-A1 | PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | MSN Laboratories Private Limited, R&D Center (IN) | 2024-06-12 | — | — | EP | claimed |
| US-11827667-B2 | Production method for guanosine derivative having fluorine atom-containing functional group at position 8 and application thereof | UNIVERSITY OF MIYAZAKI (JP) | 2023-11-28 | — | — | US | claimed |
| WO-2023090935-A1 | METHOD FOR PRODUCING AGM PEPTIDES THAT BIND SPECIFICALLY TO NUCLEOLIN | 애니젠 주식회사 | 2023-05-25 | — | — | WO | claimed |
| WO-2023012829-A1 | PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-02-09 | — | — | WO | claimed |
| US-11066439-B2 | Synthesis of liraglutide | BIOCON LIMITED (IN) | 2021-07-20 | — | — | US | claimed |
| US-20200079817-A1 | SYNTHESIS OF LIRAGLUTIDE | BIOCON LIMITED (IN) | 2020-03-12 | — | — | US | claimed |
| EP-3551643-A1 | SYNTHESIS OF LIRAGLUTIDE | Biocon Limited (IN) | 2019-10-16 | — | — | EP | claimed |
| CN-110291099-A | The synthesis of Liraglutide | 拜康有限公司 | 2019-09-27 | — | — | CN | claimed |
| CN-109790208-A | Method for preparing peptides comprising lipophilically modified lysine side chains | 赛诺菲 | 2019-05-21 | — | — | CN | claimed |
| EP-1021388-B1 | PHOSPHORYLATION PROCESS AND CATALYST | BIONERIS AB (SE) | 2003-06-25 | — | — | EP | claimed |
| EP-1309730-A2 | NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES | Nanogen Recognomics GmbH (DE) | 2003-05-14 | — | — | EP | claimed |
| US-6528655-B1 | Hydroxyphenyl diamido derivatives | PHARMACOR, INC. (CA) | 2003-03-04 | — | — | US | claimed |
| US-6479656-B1 | Phosphorylation process and catalyst | PERSTORP AB (SE) | 2002-11-12 | — | — | US | claimed |
| WO-2002026697-A2 | AROMATIC DERIVATIVES WITH HIV INTEGRASE INHIBITORY PROPERTIES | PHARMACOR, INC. (CA) | 2002-04-04 | — | — | WO | claimed |
| WO-2002014558-A2 | NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES | NANOGEN RECOGNOMICS GMBH (DE) | 2002-02-21 | — | — | WO | claimed |
| EP-1179537-A1 | SOLID PHASE PEPTIDE SYNTHESIS METHOD | Lipotec, S.A. (ES) | 2002-02-13 | — | — | EP | claimed |
| JP-2001501910-A | — | — | 2001-02-13 | — | — | JP | claimed |
| EP-1021388-A1 | PHOSPHORYLATION PROCESS AND CATALYST | PERSTORP AB (SE) | 2000-07-26 | — | — | EP | claimed |
| WO-1997034853-A1 | PHOSPHORYLATION PROCESS AND CATALYST | PERSTORP AB (SE) | 1997-09-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827667-B2 | Production method for guanosine derivative having fluorine atom-containing functional group at position 8 and application thereof | RNMT, FBL, NOP2 | NPC1 2063/4885RAB9A 1390/4885HPGD 1034/4885 |
| US-11066439-B2 | Synthesis of liraglutide | GLP1R, GIPR, IAPP | NPC1 3897/4885RAB9A 3335/4885HPGD 4293/4885 |
| US-20200079817-A1 | SYNTHESIS OF LIRAGLUTIDE | GLP1R, GIPR, IAPP | NPC1 3897/4885RAB9A 3335/4885HPGD 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.